Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris

American Journal of Geriatric Cardiology

Volumn 16, Issue 4, 2007, Pages 216-221

  Rich, Michael W ^a   Crager, Michael ^a,b   McKay, Charles R ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETANILIDE DERIVATIVE; PIPERAZINE DERIVATIVE; RANOLAZINE;

AGED; ANGINA PECTORIS; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG TOXICITY; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ACETANILIDES; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 35248835629     PISSN: 10767460     EISSN: 1751715X     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2007.07119.x     Document Type: Article

References (14)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
2. American Heart Association. Older Americans and cardiovascular diseases-statistics. http://www.americanheart. org/downloadable/heart/1136584495498OlderAm06.pdf. Accessed November 1, 2006.
3. Mangoni A.A. Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations. Drugs Aging. 2005;22:913-941.
4. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-316.
5. Stone PH, Gratsiansky NA, Blokhin A, et al; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48:566-575.
6. Noble D, Noble P.J. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodiumcalcium overload. Heart. 2006;92(suppl 4):iv1-iv5.
7. Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J Suppl. 2006;8:A10-A13.
8. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375-1382.
9. Thomas EJ, Brennan T.A. Incidence and types of preventable adverse events in elderly patients: population based review of medical records. B.M.J. 2000;320:741-744.
10. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
11. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina. The Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007;49:1027-1034.
12. Williams MA, Maresh CM, Esterbrooks DJ, et al. Early exercise training in patients older than age 65 years compared with that in younger patients after acute myocardial infarction or coronary artery bypass grafting. Am J Cardiol. 1985;55:263-266.
13. Lai S, Kaykha A, Yamazaki T, et al. Treadmill scores in elderly men. J Am Coll Cardiol. 2004;43:606-615.
14. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.MERLIN-TIMI 36 investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trialAm Heart J. 2006;151:1186.e1-1186.e9.